AAAAAA

   
Results: 1-23 |
Results: 23
Breakthrough of Ac-225 and its radionuclide daughters from an Ac-225/Bi-213 generator: development of new methods, quantitative characterization, andimplications for clinical use
Authors: Ma, DH McDevitt, MR Finn, RD Scheinberg, DA
Citation: Dh. Ma et al., Breakthrough of Ac-225 and its radionuclide daughters from an Ac-225/Bi-213 generator: development of new methods, quantitative characterization, andimplications for clinical use, APPL RAD IS, 55(5), 2001, pp. 667-678
Rapid preparation of short-lived alpha particle emitting radioimmunopharmaceuticals
Authors: Ma, DH McDevitt, MR Finn, RD Scheinberg, DA
Citation: Dh. Ma et al., Rapid preparation of short-lived alpha particle emitting radioimmunopharmaceuticals, APPL RAD IS, 55(4), 2001, pp. 463-470
Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients
Authors: Tanswell, P Garin-Chesa, P Rettig, WJ Welt, S Divgi, CR Casper, ES Finn, RD Larson, SM Old, LJ Scott, AM
Citation: P. Tanswell et al., Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients, BR J CL PH, 51(2), 2001, pp. 177-180
Relative therapeutic efficacy of I-125- and I-131-labeled monoclonal antibody A33 in a human colon cancer xenograft
Authors: Barendswaard, EC Humm, JL O'Donoghue, JA Sgouros, G Finn, RD Scott, AM Larson, SM Welt, S
Citation: Ec. Barendswaard et al., Relative therapeutic efficacy of I-125- and I-131-labeled monoclonal antibody A33 in a human colon cancer xenograft, J NUCL MED, 42(8), 2001, pp. 1251-1256
PET imaging of Y-86-labeled anti-Lewis Y monoclonal antibodies in a nude mouse model: Comparison between Y-86 and In-111 radiolabels
Authors: Lovqvist, A Humm, JL Sheikh, A Finn, RD Koziorowski, J Ruan, S Pentlow, KS Jungbluth, A Welt, S Lee, FT Brechbiel, MW Larson, SM
Citation: A. Lovqvist et al., PET imaging of Y-86-labeled anti-Lewis Y monoclonal antibodies in a nude mouse model: Comparison between Y-86 and In-111 radiolabels, J NUCL MED, 42(8), 2001, pp. 1281-1287
Escherichia coli RNA polymerase cove and holoenzyme structures
Authors: Finn, RD Orlova, EV Gowen, B Buck, M van Heel, M
Citation: Rd. Finn et al., Escherichia coli RNA polymerase cove and holoenzyme structures, EMBO J, 19(24), 2000, pp. 6833-6844
Evaluation of C-11-colchicine for PET imaging of multiple drug resistance
Authors: Levchenko, A Mehta, BM Lee, JB Humm, JL Augensen, F Squire, O Kothari, PJ Finn, RD Leonard, EF Larson, SM
Citation: A. Levchenko et al., Evaluation of C-11-colchicine for PET imaging of multiple drug resistance, J NUCL MED, 41(3), 2000, pp. 493-501
Optimizing the sequence of combination therapy with radiolabeled antibodies and fractionated external beam
Authors: Ruan, S O'Donoghue, JA Larson, SM Finn, RD Jungbluth, A Welt, S Humm, JL
Citation: S. Ruan et al., Optimizing the sequence of combination therapy with radiolabeled antibodies and fractionated external beam, J NUCL MED, 41(11), 2000, pp. 1905-1912
Low energy cyclotron production and chemical separation of "no carrier added" iodine-124 from a reusable, enriched tellurium-124 dioxide/aluminum oxide solid solution target?
Authors: Sheh, Y Koziorowski, J Balatoni, J Lom, C Dahl, JR Finn, RD
Citation: Y. Sheh et al., Low energy cyclotron production and chemical separation of "no carrier added" iodine-124 from a reusable, enriched tellurium-124 dioxide/aluminum oxide solid solution target?, RADIOCH ACT, 88(3-4), 2000, pp. 169-173
Pharmacokinetics and microdistribution of polyethylene glycol-modified humanized A33 antibody targeting colon cancer xenografts
Authors: Deckert, PM Jungbluth, A Montalto, N Clark, MA Finn, RD Williams, C Richards, EC Panageas, KS Old, LJ Welt, S
Citation: Pm. Deckert et al., Pharmacokinetics and microdistribution of polyethylene glycol-modified humanized A33 antibody targeting colon cancer xenografts, INT J CANC, 87(3), 2000, pp. 382-390
Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography
Authors: Guillem, JG Puig-La Calle, J Akhurst, T Tickoo, S Ruo, L Minsky, BD Gollub, MJ Klimstra, DS Mazumdar, M Paty, PB Macapinlac, H Yeung, H Saltz, L Finn, RD Erdi, Y Humm, J Cohen, AM Larson, S
Citation: Jg. Guillem et al., Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography, DIS COL REC, 43(1), 2000, pp. 18-24
Imaging brain tumor proliferative activity with [I-124]iododeoxyuridine
Authors: Blasberg, RG Roelcke, U Weinreich, R Beattie, B von Ammon, K Yonekawa, Y Landolt, H Guenther, I Crompton, NEA Vontobel, P Missimer, J Maguire, RP Koziorowski, J Knust, EJ Finn, RD Leenders, KL
Citation: Rg. Blasberg et al., Imaging brain tumor proliferative activity with [I-124]iododeoxyuridine, CANCER RES, 60(3), 2000, pp. 624-635
An alpha-particle emitting antibody ([Bi-213]J591) for radioimmunotherapy of prostate cancer
Authors: McDevitt, MR Barendswaard, E Ma, D Lai, L Curcio, MJ Sgouros, G Ballangrud, AM Yang, WH Finn, RD Pellegrini, V Geerlings, MW Lee, M Brechbiel, MW Bander, NH Cordon-Cardo, C Scheinberg, DA
Citation: Mr. Mcdevitt et al., An alpha-particle emitting antibody ([Bi-213]J591) for radioimmunotherapy of prostate cancer, CANCER RES, 60(21), 2000, pp. 6095-6100
An Ac-225/Bi-213 generator system for therapeutic clinical applications: construction and operation
Authors: McDevitt, MR Finn, RD Sgouros, G Ma, DS Scheinberg, DA
Citation: Mr. Mcdevitt et al., An Ac-225/Bi-213 generator system for therapeutic clinical applications: construction and operation, APPL RAD IS, 50(5), 1999, pp. 895-904
The search for consistency in the manufacture of PET radiopharmaceuticals
Authors: Finn, RD
Citation: Rd. Finn, The search for consistency in the manufacture of PET radiopharmaceuticals, ANN NUCL M, 13(6), 1999, pp. 379-382
Pfam 3.1: 1313 multiple alignments and profile HMMs match the majority of proteins
Authors: Bateman, A Birney, E Durbin, R Eddy, SR Finn, RD Sonnhammer, ELL
Citation: A. Bateman et al., Pfam 3.1: 1313 multiple alignments and profile HMMs match the majority of proteins, NUCL ACID R, 27(1), 1999, pp. 260-262
Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: Bi-213-HuM195 (anti-CD33) in patients with leukemia
Authors: Sgouros, G Ballangrud, AM Jurcic, JG McDevitt, MR Humm, JL Erdi, YE Mehta, BM Finn, RD Larson, SM Scheinberg, DA
Citation: G. Sgouros et al., Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: Bi-213-HuM195 (anti-CD33) in patients with leukemia, J NUCL MED, 40(11), 1999, pp. 1935-1946
Preparation of alpha-emitting Bi-213-labeled antibody constructs for clinical use
Authors: McDevitt, MR Finn, RD Ma, D Larson, SM Scheinberg, DA
Citation: Mr. Mcdevitt et al., Preparation of alpha-emitting Bi-213-labeled antibody constructs for clinical use, J NUCL MED, 40(10), 1999, pp. 1722-1727
I-131 radioimmunotherapy and fractionated external beam radiotherapy: Comparative effectiveness in a human tumor xenograft
Authors: Barendswaard, EC O'Donoghue, JA Larson, SM Tschmelitsch, J Welt, S Finn, RD Humm, JL
Citation: Ec. Barendswaard et al., I-131 radioimmunotherapy and fractionated external beam radiotherapy: Comparative effectiveness in a human tumor xenograft, J NUCL MED, 40(10), 1999, pp. 1764-1768
Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: Pharmacokinetics, bioactivity, toxicity and chemistry
Authors: Nikula, TK McDevitt, MR Finn, RD Wu, CC Kozak, RW Garmestani, K Brechbiel, MW Curcio, MJ Pippin, CG Tiffany-Jones, L Geerlings, MW Apostolidis, C Molinet, R Geerlings, MW Gansow, OA Scheinberg, DA
Citation: Tk. Nikula et al., Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: Pharmacokinetics, bioactivity, toxicity and chemistry, J NUCL MED, 40(1), 1999, pp. 166-176
[F-18]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic I-131 whole body scans and elevated serum thyroglobulin levels
Authors: Wang, WP Macapinlac, H Larson, SM Yeh, SDJ Akhurst, T Finn, RD Rosai, J Robbins, RJ
Citation: Wp. Wang et al., [F-18]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic I-131 whole body scans and elevated serum thyroglobulin levels, J CLIN END, 84(7), 1999, pp. 2291-2302
The C-terminal 12 amino acids of sigma(N) are required for structure and function
Authors: Studholme, DJ Finn, RD Chaney, MK Buck, M
Citation: Dj. Studholme et al., The C-terminal 12 amino acids of sigma(N) are required for structure and function, ARCH BIOCH, 371(2), 1999, pp. 234-240
Utility of F-18-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases
Authors: Fong, YM Saldinger, PF Akhurst, T Macapinlac, H Yeung, H Finn, RD Cohen, A Kemeny, N Blumgart, LH Larson, SM
Citation: Ym. Fong et al., Utility of F-18-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases, AM J SURG, 178(4), 1999, pp. 282-287
Risultati: 1-23 |